Drug manufacturers are doing a better job of providing the Health Resources and Services Administration (HRSA) with timely and accurate data needed to verify their 340B ceiling prices, the head of the federal 340B drug pricing program indicated today. Nonetheless, some still either have not created HRSA accounts to upload the figures or miss deadlines for submitting their data, she said.
Speaking this morning via Skype from suburban Washington, D.C., to 340B Coalition winter conference attendees in San Diego, Calif., HRSA Office of Pharmacy Affairs (OPA) Director Adm. Krista Pedley gave an update on the rough first anniversary of the congressionally mandated 340B ceiling price secure website. Known formally as the pricing component of the 340B OPA Information System (OPAIS), the secure website gives 340B covered entities view-only access to verified 340B ceiling prices for covered outpatient drugs. Congress told the Secretary of Health and Human Services (HHS) to build the website in 2010 in the Affordable Care Act. Its opening after a nine-year delay was considered a major win for 340B healthcare providers.
Drug manufacturers are doing a better job of providing the Health Resources and Services Administration (HRSA) with timely and accurate data needed to verify their 340B ceiling prices, the head of the federal 340B drug pricing program indicated today. Nonetheless, […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
